1. Home
  2. ETJ vs PHAR Comparison

ETJ vs PHAR Comparison

Compare ETJ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

ETJ

Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

HOLD

Current Price

$8.79

Market Cap

590.9M

Sector

Finance

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$17.06

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETJ
PHAR
Founded
2007
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
590.9M
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ETJ
PHAR
Price
$8.79
$17.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$38.00
AVG Volume (30 Days)
175.6K
27.8K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
8.30%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
N/A
$362,274,000.00
Revenue This Year
N/A
$25.19
Revenue Next Year
N/A
$4.47
P/E Ratio
N/A
$3,081.99
Revenue Growth
N/A
26.78
52 Week Low
$7.20
$7.50
52 Week High
$8.47
$18.30

Technical Indicators

Market Signals
Indicator
ETJ
PHAR
Relative Strength Index (RSI) 51.56 51.27
Support Level $8.77 $16.61
Resistance Level $8.94 $17.69
Average True Range (ATR) 0.09 0.79
MACD 0.01 -0.05
Stochastic Oscillator 59.48 42.82

Price Performance

Historical Comparison
ETJ
PHAR

About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: